Moreover, strategies focusing on tumour microenvironment modulation, such as inhibition of angiogenesis and immune checkpoint blockade, are being explored to enhance treatment responses in resistant HER2-positive breast cancers. Here, ERBB2 is linked to breast carcinoma.